Indication
Non-Muscle Invasive Bladder Urothelial Carcinoma
1 clinical trial
1 product
1 drug
Clinical trial
Pilot Study of an IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerStatus: Recruiting, Estimated PCD: 2026-06-01
Product
PD-L1/IDO Peptide VaccineDrug
mFOLFOX6